Maplight ML-007C-MA-212 [De Novo]
About the Study
This study is indicated for adults with schizophrenia looking for outpatient treatment.
The goal of this study is to assess the long-term efficacy, safety, and tolerability of ML-007C-MA in adult participants living with symptoms of schizophrenia. For this study, ML-007C-MA is taken orally BID (twice a day), approximately 12 hours apart, within approximately 1 hour of consuming food. ML-007C-MA is provided as a tablet in dose strengths of 105/1.5 mg, 105/3 mg, and 165/3 mg. The dose of 210/3 mg requires the ingestion of two 105/1.5 mg tablets. Study drug will be dispensed to participants to take home.
This study is sponsored by Maplight Therapeutics.
Eligibility
You may be eligible to participate in this study if you:
are between the ages of 18-64 years old
have a primary diagnosis of schizophrenia based on DSM-5 criteria, and confirmed by the MINI assessment
are willing and able to commit to a year long study
have a reliable study informant/caregiver available and willing to participate in relevant study assessments.
If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.
If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.